Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» RNAi
RNAi
Alnylam, Vir team up to develop siRNAs to tackle COVID-19
Fierce Biotech
Wed, 03/4/20 - 10:52 am
Alnylam
Vir Biotechnology
RNAi
coronaviruses
COVID-19
siRNA
After big year, RNAi drugmakers compete to prove what comes next
BioPharma Dive
Sat, 01/18/20 - 07:37 pm
RNAi
JPMHC 2020
Alynylam
Arrowhead Pharmaceuticals
Dicerna Pharmaceuticals
JPM: Alnylam CEO looks to action-packed 2020 on the heels of Givlaari approval
Fierce Pharma
Tue, 01/14/20 - 10:44 am
Alnylam
RNAi
Givlaari
John Maraganore
JPMHC 2020
With trial win, Alnylam to seek approval for first treatment of rare kidney disease
Biopharma Dive
Tue, 12/17/19 - 10:29 am
Alnylam
lumasiran
clincial trials
RNAi
kidney disease
Primary Hyperoxaluria
3 Soaring Biotech Stocks to Watch in December
Motley Fool
Mon, 12/2/19 - 10:40 am
Arrowhead Pharmaceuticals
RNAi
Adverum Biotechnologies
gene therapy
ADVM-022
Arqule
ARQ-531
Second RNAi Drug Approved: Biotech Investors Should Pay Attention to This New Drug Class
Motley Fool
Sat, 11/23/19 - 04:05 pm
RNAi
Givlaari
Alnylam
FDA's rapid review pace nets an early approval for Alnylam's second drug
Biopharma Dive
Wed, 11/20/19 - 10:51 pm
FDA
Alnylam
Givlaari
givosiran
RNAi
porphyria
Dicerna scores broad, 'rest of liver' deal with Novo Nordisk, bagging $225M in cash to hit some 30 targets with RNAi platform
Endpoints
Mon, 11/18/19 - 11:33 pm
Dicerna
Novo Nordisk
liver disease
RNAi
Roche pays $200M for rights to Dicerna's hepatitis B RNAi drug
Fierce Biotech
Thu, 10/31/19 - 10:29 am
Roche
Dicerna Pharmaceuticals
RNAi
hepatitis B
DCR-HBVS
Alnylam's Onpattro back in the game against Ionis, thanks to NICE U-turn
Fierce Pharma
Tue, 07/9/19 - 06:32 pm
Ionis
Tegsedi
RNAi
Alnylam
Onpattro
NICE
RNAi Therapeutics Focused Sirnaomics Closes $47 Million Series C Round
CP Wire
Fri, 04/26/19 - 10:06 am
Sriaomics
STP705
cholangiocarcinoma
hepatocellular carcinoma
RNAi
Alnylam Gets $800M From Regeneron to Bring RNAi to Eye, Brain Diseases
Xconomy
Mon, 04/8/19 - 09:56 am
Alnylam
Regeneron
RNAi
eye health
brain diseases
After landing a historic FDA OK, Alnylam chief John Maraganore scores a big raise
Endpoints
Fri, 03/22/19 - 10:11 pm
Alnylam
RNAi
Pharma CEOs
John Maraganore
exective pay
Data in Hand, Alnylam To Seek OK For Second RNAi Drug
Xconomy
Wed, 03/6/19 - 10:07 am
Alnylam
RNAi
FDA
acute hepatic porphyria
givosiran
Here's Why Arrowhead Pharmaceuticals Shot 237.5% Higher in 2018
Motley Fool
Sun, 01/13/19 - 11:36 am
Arrowhead Pharmaceuticals
RNAi
Alnylam CEO talks politics, gene therapy and not becoming Pfizer
BioPharma Dive
Sun, 12/16/18 - 12:12 am
Alnylam
RNAi
Onpattro
Pharma CEOs
John Maraganore
Here's Why Arrowhead Pharmaceuticals Jumped 14.1% in November
Motley Fool
Mon, 12/10/18 - 07:04 pm
Arrowhead Pharmaceuticals
ARO-HBV
hepatitis B
Janssen
RNAi
Alnylam's Onpattro sales look 'disappointing' in early days of RNAi launch: analyst
Fierce Pharma
Mon, 11/19/18 - 11:31 am
Alnylam
RNAi
Onpattro
hATTR amyloidosis
Alnylam seeks MHRA approval to start ALN-AAT02 phase 1/2 trial
Pharmaceutical Business Review
Thu, 10/4/18 - 06:55 pm
Alnylam
RNAi
ALN-AAT02
MHRA
UK
Johnson & Johnson pays $175M, commits to $1.6B in milestones for Arrowhead hepatitis B drug
Fierce Biotech
Thu, 10/4/18 - 10:22 am
JNJ
Arrowhead
hepatitis B
RNAi
Pages
« first
‹ previous
1
2
3
4
5
6
next ›
last »